Fosamax Osteonecrosis of the Jaw Attorney: Lawsuit Eligibility Overview

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Communication to Targeted Risk Assessment

The legacy of general health and science communication has long served as a foundation for public awareness, providing accessible information on a wide range of medical topics. Within this tradition, discussions of bone health and pharmaceutical interventions have been common, often emphasizing the importance of informed patient decision-making. As this heritage evolves, a natural progression emerges toward examining specific exposures and their potential consequences in occupational and clinical settings. The transition from broad health education to focused risk assessment is particularly relevant when considering long-term medication use and its implications for patient safety. In the context of mass production and healthcare delivery, the shift from general wellness guidance to targeted exposure analysis becomes critical. This pivot acknowledges that certain pharmaceutical agents, when used over extended periods, may present distinct challenges that warrant careful scrutiny. The focus now turns to understanding how prolonged exposure to bisphosphonate therapies, such as those used in osteoporosis management, can be associated with adverse outcomes in specific patient populations. This transition maintains the neutral, evidence-informed tone of health communication while narrowing the scope to address practical concerns regarding medication-related risks and their management in clinical practice.

Understanding Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication prescribed to treat osteoporosis and other bone conditions. A known adverse effect associated with its use is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw. This narrative provides an evidence-grounded overview of the clinical presentation, pharmacological context, mechanistic pathways, and risk considerations for patients evaluating potential legal action. The clinical presentation of ONJ involves the death of bone tissue in the mandible or maxilla, often presenting as exposed bone that fails to heal after dental procedures or spontaneously. The condition is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors include invasive dental procedures such as tooth extraction, dental implants, and boney surgery; diagnosis of cancer; concomitant therapies like chemotherapy, corticosteroids, and angiogenesis inhibitors; poor oral hygiene; and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Multiscale characterization of jawbone tissue provides comprehensive information that can help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Pharmacology and Mechanistic Pathways

Fosamax works by inhibiting bone resorption, which helps increase bone density in conditions like osteoporosis. However, this mechanism can also suppress normal bone turnover, potentially leading to adverse effects. The time to onset of ONJ symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Among specialists surveyed, zoledronate and alendronate (the active ingredient in Fosamax) were prescribed more frequently than other antiresorptive medications (https://pubmed.ncbi.nlm.nih.gov/40604825/). The exact mechanism by which bisphosphonates like Fosamax contribute to ONJ is not fully understood, but it is believed to involve suppression of bone remodeling, impaired blood supply, and altered immune response. The jawbone's unique structure and high rate of remodeling may make it particularly susceptible. Multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Clinical judgment of the treating physician and/or oral surgeon should guide the management plan of each patient based on individual benefit/risk assessment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Adequacy of Warnings and Legal Considerations

The FDA-approved labeling for Fosamax includes a warning under section 5.4 specifically addressing osteonecrosis of the jaw. The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It also notes that ONJ can occur spontaneously and is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label lists known risk factors and advises that discontinuation of bisphosphonate treatment may reduce risk for patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the adequacy of these warnings may be questioned if patients were not adequately informed of the risk before starting treatment, particularly given that the condition can be severe and require care by an oral surgeon (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients who develop ONJ after taking Fosamax may consider legal action if they believe the warnings were insufficient or if they were not adequately informed of the risk. Key considerations include the timeline between exposure and documented harm, as symptoms can appear from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk may increase with longer duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Among specialists, 44% had encountered between one and four cases of medication-related osteonecrosis of the jaw in the past year, and dentists were the most frequent source of consultations regarding bisphosphonates (50.4%), followed by oral and maxillofacial surgeons (36.8%) (https://pubmed.ncbi.nlm.nih.gov/40604825/). When encountering patients with osteonecrosis, 39.2% of specialists most frequently referred them to oral and maxillofacial surgery (https://pubmed.ncbi.nlm.nih.gov/40604825/). Patients should document their medical history, including the timing of Fosamax use, any dental procedures, and the onset of symptoms, to support a potential claim.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it linked to osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate used to treat osteoporosis. A known adverse effect is osteonecrosis of the jaw (ONJ), where jawbone tissue dies and fails to heal, often after dental procedures. The risk may increase with longer use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the symptoms and risk factors for ONJ?

Symptoms include exposed, non-healing bone in the jaw. Risk factors include invasive dental procedures, cancer, chemotherapy, corticosteroids, poor oral hygiene, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long after starting Fosamax can ONJ develop?

Onset can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients improve after stopping, but some may have recurrence if rechallenged.

Are the warnings about ONJ on Fosamax labels adequate?

The FDA label includes a warning about ONJ, but some patients may not have been adequately informed before starting treatment. Legal action may be considered if warnings were insufficient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.